前蛋白转化酶枯草溶菌素9抑制剂的研究进展  

Research Advances in Proprotein Convertase Subtilisin / kexin Type 9 Inhibitors

作　　者：曾雨薇[1] 罗素新[1] 刘洪沛[1] 

机构地区：[1]重庆医科大学附属第一医院心血管内科,重庆400016

出　　处：《心血管病学进展》2015年第3期341-345,共5页Advances in Cardiovascular Diseases

基　　金：国家临床重点专科建设项目(2011-08);重庆市科委课题(CSTC2012JJA0911)

摘　　要：胆固醇尤其是低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)升高,是冠心病发病的独立危险因素。降低LDL-C被视为降低冠心病风险的关键因素。前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)通过调控低密度脂蛋白受体影响LDL-C代谢,降低LDL-C水平,成为高胆固醇血症患者治疗的新靶点。因而多种PCSK9抑制剂应运而生。目前已探索了不同途径的PCSK9抑制剂,其中单克隆抗体发展最为迅速,可能将成为一类非常有前景的调脂药物。Elevated cholesterol levels, especially elevated low density lipoprotein cholesterol （ LDL-C） levels, is an independent risk factor for incidence of coronary heart disease（ CHD）.LDL-C reduction is seen as a key factor for reducing the risk of CHD.By regulating the low density lipoprotein receptor, proprotein convertase subtilisin/kexin type 9（ PCSK9） affects LDL-C metabolism, lowers levels of LDL-C and becomes a novel target site of hypercholesterolemia therapy.Therefore varieties of PCSK9 inhibitors has emerged.Recently, different pathways of PCSK9 inhibitors have been explored, and monoclonal antibody, as the most rapidly developing one, will become a promising lipid-lowering agent.

关 键 词：高胆固醇血症 前蛋白转化酶枯草溶菌素9抑制剂 研究进展 

分 类 号：R541.4[医药卫生—心血管疾病] R589.2[医药卫生—内科学]